Drug intelligence / Profile preview

R130

Development stage: Phase 1
Lead developer: Shanghai Yunying Medical Technology
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intratumoral

Overview

R130 is a recombinant oncolytic herpes simplex virus type I (HSV-1) developed by Shanghai Yunying Medical Technology and Shanghai Yunying Bio-pharm Technology Co. LTD. It is engineered to carry genes coding for anti-CD3 scFv, CD86, PD1, and HSV2-US11. This oncolytic virus is being investigated for the treatment of various advanced and relapsed/refractory solid tumors, including head and neck tumors, bone and soft tissue tumors, cervical cancer, endometrial cancer, and ovarian cancer. It is administered intratumorally.

Other names: Oncolytic Virus Injection (R130)Recombinant oncolytic herpes simplex virus type I (R130)Recombinant oncolytic herpes simplex virus type 1 (R130)

Targets

CD86 (T-lymphocyte activation antigen CD86)PDCD1 (Programmed cell death protein 1 receptor)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on R130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R130.

Explore the full profile